Monoclonal antibodies (mAb) are powerful tools which are widely used in every phase of the biomedical field from discovery research and diagnosis to therapeutics. Yet, existing methods for isolating mAb-producing hybridomas are tedious and time consuming and often not amenable to high-throughput screening. In particular, the most challenging, time-consuming, and labor-intensive phase in generating mAbs is the Limiting Dilution Subcloning (LDS) step.

We offer a unique technology for the rapid production of hybridoma & reduce Hybridoma Screening & Cloning Time by 75%. Using a genetically-modified myeloma partner, the kit creates hybridomas capable of both secreting and surface-expressing antigen specific antibodies, enabling screening and selection of positive clones by FACS or magnetic separation in matters of hours, resulting in improved efficiency for detection of highly specific mAb.

Our Partners